Business Practice

The efforts of CDMOs have been absolutely crucial in the pandemic response. We ask five CDMO gurus how they reacted to COVID-19.

Part 2 of our roundtable discussion with CDMOs covers outsourcing preferences, the demand for mRNA, and more.

In this video interview, Mike Rea explains why each drug needs its own launch strategy.

The way the pharma industry has traditionally handled clinical trials does not make participation easy.

We speak with the authors of two studies into extreme increases in US drug pricing, and attempts by lawmakers to bring the price-jackers into line.

We get the lowdown on the Reputation Index, which was recently published by the Association of the British Pharmaceutical Industry.

The pharma industry is one of the biggest targets for cybercrime. How can companies avoid succumbing to attack?

Sitting Down With… Evelina Vågesjö, Chief Executive Officer at Ilya Pharma, Sweden.

On the 70th anniversary of death Henrietta Lacks, we examine her contributions to science and what they mean for modern research.

Mike Rea of IDEA Pharma shares his thoughts on what players in pharma positioning are getting right – and wrong.